Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in drug development for antiretroviral therapies

Expert Opinion on Investigational Drugs

Volumn 18, Issue 4, 2009, Pages 549-553

  Temesgen, Zelalem ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXY 2' FLUORO 5' O PHOSPHONOMETHYLADENOSINE; AMDOXOVIR; ANTIRETROVIRUS AGENT; ATI 0917; BIT 225; BRYOSTATIN 1; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HYDROXYUREA; IDX 899; IQP 0528; LAMIVUDINE PLUS ZIDOVUDINE; PLACEBO; PRO 140; RILPIVIRINE; UNCLASSIFIED DRUG; VS 411; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESEARCH; DRUG UPTAKE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NONHUMAN; RASH;

ANIMALS; ANTI-RETROVIRAL AGENTS; DRUG DISCOVERY; HIV INFECTIONS; HUMANS; PUERTO RICO;

EID: 67649580218     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902806418     Document Type: Conference Paper

References (14)

1. Murphy RL, RFS-AMDX-203 Team. Amdoxovir combined with lowd Dose AZT for HIV-1 therapy [abstract 45]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
2. Asif G, Hurwitz SJ, Tharnish PM, et al. Lack of pharmacokinetic interaction for low and normal dose zidovudine with amdoxovir in HIV-1 infected individuals [abstract 71]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
3. Ray AS, LaFlamme G, Grant D, et al. Low potential for class related toxicity of next generation nucleotide analog GS-9148 [abstract 47]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
4. Lefebvre E. A new era in HIV-antiretroviral therapy: darunavir, etravirine and TMC278 [abstract 46]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
5. Lori F, Stevens M. Development of VS411, a virostatic drug fixed dose combination (FDC) designed to inhibit both HIV and immune hyperactivation [abstract 11]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
6. Jacobson JM, Thompson MA, Fischl MA, et al. Antiviral activity and tolerability of PRO 140, a humanized monoclonal antibody to CCR 5 [abstract 75]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
7. Mayers D, Murphy R, Zala C, et al. IDX899: a novel once-a-day second generation NNRT I for the treatment of HIV/AIDS [abstract 43]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
8. Ewart GD, Sutherland T, Gage PW, Cox GB. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol 1996;70(10):7108-7115 (Pubitemid 26307427)
9. Ewart GD, Nasr N, Naif H, et al. Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrob Agents Chemother 2004;48(6):2325-2330 (Pubitemid 38691643)
10. Khoury G, Ewart G, Luscombe C, et al. Inhibiting Vpu function with the novel compound BIT225 results in inhibition of HIV-1 release from human macrophage reservoirs [abstract 12]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
11. Castor TP, Munoz MA, Moreno S, Munoz E. Combination therapy for treating HIV latency [abstract 16]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
12. Hartman TL, Buckheit Jr RW. Inhibition of late stage events in HIV-1 replication: discovery and development of therapeutic compounds with effects on viral RNA synthesis which potentially target rev function [abstract 17]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
13. Buckheit Jr Rw, Hartman TL, Yang L, Watson KM. Development of pyrimidinedione NNRT is with a high genetic barrier to resistance [abstract 10]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico
14. Watson KM, Yang L, Buckheit CE, Buckheit Jr RW. Development of the dual-acting pyrimidinedione IQP0528 as a vaginal topical anti-HIV microbicide [abstract 28]. Program and abstracts of HIV DART 2008 Frontiers in Drug Development for Antiretroviral Therapies; 2008 Dec 9-12; Puerto Rico